Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
about
Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.Topical treatment of glaucoma: established and emerging pharmacology.Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study.Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
P2860
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@en
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@nl
type
label
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@en
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@nl
prefLabel
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@en
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@nl
P2093
P2860
P1433
P1476
Additive Intraocular Pressure ...... mal Tolerated Medical Therapy.
@en
P2093
Akitaka Tsujikawa
Kaori Ukegawa
Shino Sato
P2860
P2888
P304
P356
10.1007/S12325-016-0389-3
P407
P577
2016-07-20T00:00:00Z